Early diagnosis of heart failure improves patient outcomes, however diagnosis is complex and often delayed. This study evaluates a digital pathway for heart failure diagnosis, showing it reduces time to diagnosis and treatment initiation, with an incremental cost of 5,700GBP per quality adjusted life-year (QALY) gained over a lifetime. The pathway is cost-effective for the UK National Health Service at 20,000GBP per QALY threshold, however data uncertainties remain.

The Health Economics and Health Technology Assessment (HEHTA) Unit at the University of Glasgow (where NM, OW, AD are based) received a research grant from AstraZeneca to conduct this research. MP has received research funding from Boehringer Ingelheim, Roche, SQ Innovations, Astra Zeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Pharmacosmos, and consultancy and Trial committees: Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Novartis, Astra Zeneca, Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Takeda, Cardiorentis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R Lifesciences. DJL has received grants from AstraZeneca, Roche, Qure.ai. and has received speakers honoraria from AstraZeneca and Boerhinger Ingelheim. CM has received research grant for OPERA (Astra Zeneca) and speaker honoraria from Astra Zeneca and Novartis. LM has received funding from AstraZeneca for education talks. KB has no conflicts of interest. RTC has received consultancy honoraria from Bayer for speaking honoraria from AstraZeneca.

This work was funded by an unrestricted grant from AstraZeneca.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of West of Scotland Research Ethics Committee (REC) (20/SW/0182) and the Health Research Authority (HRA) gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Study data and model will be shared on a reasonable request to the corresponding author.